Evonik stock: Seven analyst houses set EUR 20.00 as the consensus target for Evonik stock

Published on 10/23/2026 at 16:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock stands 3.07 percent below its 52-week high. It costs EUR 21.17 on October 23, 2026, down 0.05 percent versus the Xetra close.

Analyst target and reporting date

Seven analyst houses set a 12-month consensus target of EUR 20.00 on October 20, 2026.
Evonik's market capitalization stood at EUR 9.9 billion on October 23, 2026.
Evonik stock costs EUR 21.17 at Lang & Schwarz on October 23, 2026 at 5:41 p.m. CEST, 0.05 percent below the Xetra close of October 23, 2026 at EUR 21.18.
Evonik is scheduled to report third-quarter 2026 results on November 3, 2026.

Aquarellmalerei der Essener Skyline mit Villa Hügel und Industriesilhouetten am Baldeneysee — Evonik Industries DE000EVNK013 als Aquarellmalerei der Essener Stadtlandschaft mit Industriesilhouette am Baldeneysee, Illustration mit AI erstellt.

Seven analyst houses put Evonik's 12-month consensus target at EUR 20.00 as of October 20, 2026, according to Boerse Express. The group consensus comprises two Buy ratings, four Hold ratings and one Sell rating. At Lang & Schwarz, Evonik was trading at EUR 21.17 on October 23, 2026 at 5:41 p.m. CEST, down 0.05 percent versus the Xetra close of October 23, 2026 at EUR 21.18, leaving the consensus target 5.53 percent below the price.

Why does the consensus stay below price?

The analyst picture sets a clear numerical counterpoint to the share price. The EUR 20.00 median target is EUR 1.17 below the Lang & Schwarz quote, while the target range extends from EUR 14.00 to EUR 22.00, according to Boerse Express on October 20, 2026. The spread shows that the seven-house consensus is not a single directional call, but the central estimate remains below the market quotation.

Stock remains below its yearly high

Evonik's price position is firm within its 52-week band. The stock stood 3.07 percent below its EUR 21.84 high and 69.50 percent above its EUR 12.49 low on October 23, 2026. Trading volume reached 1,395,032 shares, while market capitalization was EUR 9.9 billion on the same date. Those figures place the stock close to the upper end of its annual range without turning the daily move into a separate trend signal.

Market value and next report

The next scheduled reporting date is November 3, 2026, when Evonik is due to publish its third-quarter results. The date appears on the company's investor-relations calendar, which lists the report as third-quarter 2026 coverage through Evonik. Until then, the market has a defined timetable against which the EUR 20.00 consensus target can be reassessed.

Comparison with peers

Evonik: down 0.05 percent, market capitalization EUR 9.9 billion, as of October 23, 2026.

BASF (Xetra, EUR): down 0.10 percent, market capitalization EUR 45.1 billion, as of October 23, 2026.

Wacker Chemie (Xetra, EUR): down 4.12 percent, market capitalization EUR 3.9 billion, as of October 23, 2026.

What the next report will clarify

The November 3, 2026 report will provide the next dated operating checkpoint for the stock. For investors, the key numerical tension is already visible: Evonik trades at EUR 21.17, while the seven-house median target is EUR 20.00 and the 52-week high is EUR 21.84.

Evonik stock remains near its yearly high

The share price is 3.07 percent below its 52-week high, while the consensus target sits 5.53 percent below the Lang & Schwarz quote. The next scheduled report is November 3, 2026.

The further course of trading is shown by the continuously updated real-time quote of Evonik stock.